UBS Group
CMMB

UBS Group’s Chemomab Therapeutics CMMB Stock Holding History

UBS Group’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$13 – 10504
2026
Q1 		$13 Sell
8
-2,245
-100% -$3.84K ﹤0.01% 10316
2025
Q4 		$3.72K Buy
2,253
+2,154
+2,176% +$5.71K ﹤0.01% 8963
2025
Q3 		$260 Hold
99
– – ﹤0.01% 9772
2025
Q2 		$461 Sell
99
-122
-55% -$603 ﹤0.01% 9822
2025
Q1 		$962 Buy
221
+100
+83% +$702 ﹤0.01% 9602
2024
Q4 		$878 Sell
121
-451
-79% -$2.85K ﹤0.01% 9360
2024
Q3 		$3.59K Buy
+572
New +$3.21K ﹤0.01% 8247
2023
Q4 		– Sell
-35
Closed -$126 – 9369
2023
Q3 		$126 Buy
35
+32
+1,067% +$150 ﹤0.01% 8829
2023
Q2 		$16 Sell
3
-100
-97% -$631 ﹤0.01% 8708
2023
Q1 		$653 Sell
103
-1,054
-91% -$8.27K ﹤0.01% 8938
2022
Q4 		$14.8K Sell
1,157
-65
-5% -$561 ﹤0.01% 8045
2022
Q3 		$12K Buy
+1,222
New +$15.7K ﹤0.01% 8150
2022
Q2 		– Sell
-221
Closed -$4K – 10379
2022
Q1 		$4K Sell
221
-240
-52% -$4.73K ﹤0.01% 9277
2021
Q4 		$13K Buy
461
+23
+5% +$816 ﹤0.01% 8440
2021
Q3 		$19K Buy
438
+403
+1,151% +$24.5K ﹤0.01% 7199
2021
Q2 		$3K Sell
35
-174
-83% -$17K ﹤0.01% 8787
2021
Q1 		$24K Buy
+209
New +$41.6K ﹤0.01% 7202
2020
Q2 		– Sell
-34
Closed -$2K – 7972
2020
Q1 		$2K Buy
+34
New +$2.49K ﹤0.01% 7600
2019
Q3 		– Sell
-22
Closed -$6K – 8019
2019
Q2 		$6K Sell
22
-21
-49% -$7.3K ﹤0.01% 7302
2019
Q1 		$19K Buy
+43
New +$21.7K ﹤0.01% 6339

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

UBS Group's CMMB Position: Q2 2026 in Review

UBS Group sold out of Chemomab Therapeutics (CMMB) in Q2 2026, closing a stake of 8 shares — an estimated $13 sold.

UBS Group first reported a position in CMMB in Q1 2019 and held it in 20 quarters. The position peaked at $24K in Q1 2021. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • UBS Group reported no remaining Chemomab Therapeutics position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 8 Chemomab Therapeutics shares in Q2 2026, an estimated $13.
  • UBS Group first reported a position in Chemomab Therapeutics in Q1 2019 and held it in 20 quarters.
  • UBS Group's Chemomab Therapeutics position peaked at $24K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.